

Lynn L Silver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6422714/publications.pdf>

Version: 2024-02-01

43
papers

9,265
citations

168829

31
h-index

325983

40
g-index

47
all docs

47
docs citations

47
times ranked

12334
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0199121.	1.4	103
2	Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies. <i>SLAS Discovery</i> , 2019, 24, 440-456.	1.4	7
3	Analysis of the clinical antibacterial and antituberculosis pipeline. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e40-e50.	4.6	161
4	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	4.6	3,672
5	Fosfomycin: Mechanism and Resistance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a025262.	2.9	205
6	What is an "ideal" antibiotic? Discovery challenges and path forward. <i>Biochemical Pharmacology</i> , 2017, 133, 63-73.	2.0	141
7	The Antibiotic Future. <i>Topics in Medicinal Chemistry</i> , 2017, , 31-67.	0.4	11
8	Appropriate Targets for Antibacterial Drugs. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a030239.	2.9	51
9	A Gestalt approach to Gram-negative entry. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 6379-6389.	1.4	140
10	Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in <i>Pseudomonas aeruginosa</i> PAO1. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 936-945.	1.4	22
11	Natural products as a source of drug leads to overcome drug resistance. <i>Future Microbiology</i> , 2015, 10, 1711-1718.	1.0	32
12	New Targets for Antibacterial Compounds. , 2015, , 249-274.		0
13	70th Anniversary Collection for the Microbiology Society: <i>Journal of Medical Microbiology</i> . <i>Journal of Medical Microbiology</i> , 2015, 64, 1457-1461.	0.7	0
14	Antibacterials for any target. <i>Nature Biotechnology</i> , 2014, 32, 1102-1104.	9.4	9
15	Multitarget ligands in antibacterial research: progress and opportunities. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 143-156.	2.5	54
16	Viable screening targets related to the bacterial cell wall. <i>Annals of the New York Academy of Sciences</i> , 2013, 1277, 29-53.	1.8	50
17	Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening. , 2012, , 33-75.		21
18	Challenges of Antibacterial Discovery. <i>Clinical Microbiology Reviews</i> , 2011, 24, 71-109.	5.7	1,106

#	ARTICLE	IF	CITATIONS
19	A persistent problem. <i>Journal of Medical Microbiology</i> , 2011, 60, 267-268.	0.7	2
20	Are natural products still the best source for antibacterial discovery? The bacterial entry factor. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 487-500.	2.5	72
21	Novel broad spectrum β -lactamase inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 1175-1181.	2.4	8
22	Multi-targeting by monotherapeutic antibacterials. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 41-55.	21.5	248
23	Platensimycin is a selective FabF inhibitor with potent antibiotic properties. <i>Nature</i> , 2006, 441, 358-361.	13.7	785
24	Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?. <i>Biochemical Pharmacology</i> , 2006, 71, 996-1005.	2.0	98
25	Discovery of FabH/FabF Inhibitors from Natural Products. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 519-526.	1.4	192
26	Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors. <i>Journal of Biological Chemistry</i> , 2005, 280, 1669-1677.	1.6	105
27	A retrospective on the failures and successes of antibacterial drug discovery. <i>IDrugs: the Investigational Drugs Journal</i> , 2005, 8, 651-5.	0.7	5
28	Outbreak of <i>Klebsiella pneumoniae</i> Producing a New Carbapenem-Hydrolyzing Class A β -Lactamase, KPC-3, in a New York Medical Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4793-4799.	1.4	402
29	Novel Pyrazolo[3,4-d]pyrimidine-Based Inhibitors of <i>Staphylococcus aureus</i> DNA Polymerase III: Design, Synthesis, and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1824-1830.	2.9	57
30	Novel illudins from <i>Coprinopsis episcopalis</i> (syn. <i>Coprinus episcopalis</i>), and the distribution of illudin-like compounds among filamentous fungi. <i>Mycological Research</i> , 2003, 107, 1201-1209.	2.5	39
31	Novel inhibitors of bacterial cell wall synthesis. <i>Current Opinion in Microbiology</i> , 2003, 6, 431-438.	2.3	100
32	Design and synthesis of novel antibacterial agents with inhibitory activity against DNA polymerase III. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2185-2188.	1.0	20
33	Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis. <i>Chemistry and Biology</i> , 2001, 8, 1095-1106.	6.2	38
34	The Role of Hydrophobic Substituents in the Biological Activity of Glycopeptide Antibiotics. <i>Journal of the American Chemical Society</i> , 2000, 122, 12608-12609.	6.6	106
35	In Vitro Activities of the Potent, Broad-Spectrum Carbapenem MK-0826 (L-749,345) against Broad-Spectrum β -Lactamase and Extended-Spectrum β -Lactamase-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1170-1176.	1.4	73
36	Carbohydroxamido-oxazolidinones: antibacterial agents that target lipid A biosynthesis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 313-318.	1.0	46

#	ARTICLE	IF	CITATIONS
37	Inhibition of IMP-1 metallo- β -lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. <i>FEMS Microbiology Letters</i> , 1999, 179, 289-296.	0.7	37
38	Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala. <i>Science</i> , 1999, 284, 507-511.	6.0	337
39	Reduced Immunotoxicity and Preservation of Antibacterial Activity in a Releasable Side-Chain Carbapenem Antibiotic. <i>Science</i> , 1999, 283, 703-706.	6.0	33
40	Antibacterial Agents That Inhibit Lipid A Biosynthesis. <i>Science</i> , 1996, 274, 980-982.	6.0	394
41	The <i>envA</i> Permeability/Cell Division Gene of <i>Escherichia coli</i> Encodes the Second Enzyme of Lipid A Biosynthesis. <i>Journal of Biological Chemistry</i> , 1995, 270, 30384-30391.	1.6	176
42	Screening of natural products for antimicrobial agents. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990, 9, 455-461.	1.3	87
43	The construction and replication properties of hybrid plasmids composed of the <i>r</i> -determinant of R100.1 and the plasmids pCRI or pSC201. <i>Molecular Genetics and Genomics</i> , 1979, 168, 337-340.	2.4	12